FDA Approves Alecensa (alectinib) as First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer

South San Francisco, CA -- November 6, 2017 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news